ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibited T Cell Proliferation, Reduced Inflammatory Cytokines, and Down Modulated BTLA Expression on Circulating T and B Cells in Phase 1, Progresses Into a Phase 2 Study in Atopic Dermatitis